methyl 5-amino-2-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyloxy)benzoate | 135790-64-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 5-amino-2-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyloxy)benzoate
• 英文别名: methyl 5-amino-2-[(2S,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxybenzoate
• CAS: 135790-64-6
• 化学式: C₂₂H₂₇NO₁₂
• 分子量: 497.456
• InChiKey: CMZDGOSFHJNXOW-OUUKCGNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  176
• 氢给体数：
  1
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  methyl 5-amino-2-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyloxy)benzoate 在 potassium carbonate 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 生成 methyl 2-(β-D-glucopyranosyloxy)-5-aminobenzoate
  参考文献：
  名称：

  EP1712555

  摘要：

  公开号：
• 作为产物：
  描述：

  5-硝基水杨酸 在 palladium on activated charcoal 喹啉 、 硫酸 、 氢气 、 silver(l) oxide 作用下， 以 乙酸乙酯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 13.0h， 生成 methyl 5-amino-2-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyloxy)benzoate
  参考文献：
  名称：

  Antiulcer Effect of theN-and O-β-D-Glucopyranosides of 5-Aminosalicylic Acid

  摘要：

  Starting from methyl 5-nitrosalicylate (20) the N- and O-beta-glucopyranosyl derivatives (24, 28) of 5-aminosalicylic acid were prepared. The LD50 values of these compounds were determined on mice, and the inhibitory effect of 24 (0.83 mmol/kg) and 28 (1.2 mmol/kg) on gastric ulcer on rats, induced by indomethacin was investigated.

  DOI：

  10.1002/(sici)1521-4184(19999)332:9<321::aid-ardp321>3.0.co;2-a

文献信息

• Glycoside prodrug of 5- aminosalicylic acid
  申请人：Nakamura Akio

  公开号：US20070173461A1

  公开（公告）日：2007-07-26

  An object of the present invention is to provide a therapeutic agent for ulcerative colitis which allows 5-aminosalicylic acid (5-ASA) useful as a therapeutic agent for ulcerative colitis to be efficiently delivered to the large intestine of the affected site almost without being absorbed or metabolized in the stomach or the upper part of the small intestine and is safe and can be administered over a long term. The present invention relates to 5-ASA into which D-galactose represented by the following general formula [1] has been introduced. The compound of the present invention can be efficiently delivered to the large intestine of the site of action, and is degraded by the intestinal bacterial flora, whereby 5-ASA as the active ingredient can be produced in the large intestine.

  本发明的目的是提供一种治疗溃疡性结肠炎的治疗剂，该治疗剂允许将5-氨基水杨酸（5-ASA）作为治疗溃疡性结肠炎的有效药物，几乎不被胃或小肠上部吸收或代谢，并且是安全的，可以长期使用。本发明涉及将D-半乳糖引入以下通式[1]所表示的化合物中的5-ASA。本发明的化合物可以有效地输送到作用部位的大肠，并被肠道细菌群降解，从而在大肠中产生5-ASA作为活性成分。
• PRODRUG COMPRISING 5-AMINOSALICYLATE GLYCOSIDE
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1712555A1

  公开（公告）日：2006-10-18

  An object of the present invention is to provide a therapeutic agent for ulcerative colitis which allows 5-aminosalicylic acid (5-ASA) useful as a therapeutic agent for ulcerative colitis to be efficiently delivered to the large intestine of the affected site almost without being absorbed or metabolized in the stomach or the upper part of the small intestine and is safe and can be administered over a long term. The present invention relates to 5-ASA into which D-galactose represented by the following general formula [1] has been introduced. The compound of the present invention can be efficiently delivered to the large intestine of the site of action, and is degraded by the intestinal bacterial flora, whereby 5-ASA as the active ingredient can be produced in the large intestine.

  本发明的目的是提供一种治疗溃疡性结肠炎的药物，它能将作为溃疡性结肠炎治疗药物的5-氨基水杨酸（5-ASA）有效地输送到受影响部位的大肠，几乎不在胃或小肠上部被吸收或代谢，而且安全，可长期给药。本发明涉及 5-ASA，其中引入了由以下通式[1]表示的 D-半乳糖。 本发明的化合物可以有效地输送到作用部位的大肠，并被肠道细菌菌群降解，从而在大肠中产生作为活性成分的 5-ASA。
• EP1712555
  申请人：——

  公开号：——

  公开（公告）日：——
• Antiulcer Effect of theN-and O-β-D-Glucopyranosides of 5-Aminosalicylic Acid
  作者：Ferenc Sztaricskai、Ildikó E. Takács、Ferenc Pusztai、Gábor Szabó、István Csípõ

  DOI：10.1002/(sici)1521-4184(19999)332:9<321::aid-ardp321>3.0.co;2-a

  日期：1999.9

  Starting from methyl 5-nitrosalicylate (20) the N- and O-beta-glucopyranosyl derivatives (24, 28) of 5-aminosalicylic acid were prepared. The LD50 values of these compounds were determined on mice, and the inhibitory effect of 24 (0.83 mmol/kg) and 28 (1.2 mmol/kg) on gastric ulcer on rats, induced by indomethacin was investigated.